USFDA Accepts Review for Zydus and Formycon Keytruda Biosimilar FYB206
Zydus Lifesciences Ltd 路 Press Release 路 13 Oct 2026, 3:20 pm
USFDA Accepts Review for Zydus and Formycon Keytruda Biosimilar FYB206 The USFDA accepted the Biologics License Application for FYB206, a proposed biosimilar to Keytruda (pembrolizumab), marking the first publicly announced acceptance for a Keytruda biosimilar. Developed without comparative Phase III efficacy trials via an agreed USFDA pathway, the dossier is also submitted to Health Canada, with an FDA decision expected in Q3'27. Zydus holds exclusive commercialization rights in the US and Canada, triggering a milestone payment to partner Formycon. Keytruda generated worldwide sales of USD 31.7B in 2025 and USD 16.40B in 1H'26.
Original exchange filing (PDF)
More announcements from Zydus Lifesciences Ltd
- Press Release 路 14 Nov 2026
- Completion of transaction 路 12 Nov 2026
- Transcript of the post results earnings call held on November 4, 2026. 路 07 Nov 2026
- Press Release 路 07 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Life Insurance Corporation of India 路 06 Nov 2026
- Investor Conference 路 06 Nov 2026
- Audio recording of the Company's Investor Call 路 05 Nov 2026
- Press Release 路 04 Nov 2026
